The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.

A Prospective Randomized Controlled Clinical Trial Comparing the Intra-operative Effects, Safety, Efficacy and Performance of Two Commercially Available Laser Systems in Patients Undergoing Femtosecond Laser-Assisted Cataract Surgery.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01878838

Enrollment

Registered

2013-06-17

Start date

2013-04-30

Completion date

2014-01-31

Last updated

2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cortical Cataract, Nuclear Sclerosis of the Lens, Posterior Subcapsular Cataract

Brief summary

This study compares two FDA approved Cataract Lasers.

Detailed description

The purpose of this study is to systematically evaluate the performance of two commercially available and FDA cleared femtosecond laser systems in patients undergoing femtosecond laser-assisted cataract surgery. Objective data on the repeatability and accuracy of the studied parameters will be gathered and reported as endpoints of the study. The two systems studied are the Catalys™ Precision Laser System (OptiMedica, CA, USA) and the LenSx® Laser System (Alcon Laboratories, Inc., Fort Worth, TX). Published data have suggested that the femtosecond laser is a useful tool for cataract surgery. This study is to determine whether differences or similarities exist in specific treatment parameters achieved with two FDA cleared and commercially available femtosecond laser cataract surgery platforms

Interventions

PROCEDUREFemtosecond Laser Assisted Cataract Surgery w/ Catalys Laser

Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.

PROCEDUREFemtosecond Laser Assisted Cataract Surgery w/ LenSx Laser

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

22 Years to No maximum

Healthy volunteers

Inclusion criteria

* Have grade 2 to 4 nuclear sclerotic and or cortical or posterior subcapsular cataracts with visual impairment. * Pupillary dilation of at least 6.0 mm * Axial length between 21 mm to 26 mm * Age ≥ 22 years of either gender * Require laser assisted corneal incisions, capsulotomy and nucleus segmentation * Understand and sign a written Informed Consent form * Be able to comply with the treatment and follow-up schedule

Exclusion criteria

* Enrolment in another drug or device study within the prior 3 months * History of ocular trauma * Acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised, etc.) * Uncontrolled systemic or ocular disease * Corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies, severe corneal opacities, significant corneal edema, etc) * Diminished aqueous clarity that obscures OCT imaging of the anterior lens capsule * Corneal ring and/or inlay implant(s) * Pseudoexfoliation * Known steroid IOP responder or ocular hypertension IOP \>25 mmHg by tonometry * Retinal detachment within the last 6 months * Anterior chamber depth less than 2.5 mm

Design outcomes

Primary

Measure	Time frame	Description
Cumulative Dissipated Energy	Intraoperative	The total amount of phacoemulsification energy delivered during the procedure.

Secondary

Measure	Time frame	Description
Complete Laser Capsulotomy	Intraoperative	Did the laser perform a complete capsulotomy with no tags or untreated segments.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026